Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 GlobeNewswire - Mon Mar 9, 8:05AM CDT

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured...

MNKD : 2.46 (+3.80%)
MannKind Announces Settlement of Convertible Senior Notes GlobeNewswire - Thu Mar 5, 3:30PM CST

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal...

MNKD : 2.46 (+3.80%)
MannKind to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Mar 4, 8:00AM CST

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today its attendance at two upcoming investor conferences, at which...

MNKD : 2.46 (+3.80%)
MannKind: Q4 Earnings Snapshot AP - Thu Feb 26, 7:17AM CST

MannKind: Q4 Earnings Snapshot

MNKD : 2.46 (+3.80%)
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Feb 26, 7:00AM CST

Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza ® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues...

MNKD : 2.46 (+3.80%)
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Thu Feb 19, 8:00AM CST

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced Chief Executive Officer Michael Castagna, PharmD is scheduled...

MNKD : 2.46 (+3.80%)
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 GlobeNewswire - Wed Feb 18, 8:00AM CST

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 2.46 (+3.80%)
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) GlobeNewswire - Mon Feb 9, 5:05AM CST

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 2.46 (+3.80%)
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy GlobeNewswire - Mon Jan 26, 5:05AM CST

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE...

MNKD : 2.46 (+3.80%)
MannKind Provides Business Updates and 2026 Growth Drivers GlobeNewswire - Thu Jan 8, 7:05AM CST

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 2.46 (+3.80%)

Barchart Exclusives

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock? Barchart - 23 minutes ago
Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.